))
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Manage episode 463979028 series 3382903
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.
FDA Approval January 2025:
On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting.
On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.
…
continue reading
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.
FDA Approval January 2025:
On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting.
On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.
7 episodes
Share
